Backed by the likes of Google and Merck (NYSE:MRK), Cambridge, Mass.-based LifeMine Therapeutics launched today by closing a $55 million Series A round. The company calls itself the first to “massively scale the genomic discovery of powerful new drugs from eukaryotic microbes”. LifeMine plans to use artificial intelligence to hunt down drugs hidden within the DNA […]